Elicio Therapeutics, Inc.

ELTX

US28657F1030

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
10.4 ^USD	+0.97%		+9.47%	+24.70%

Apr. 05	Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	CI
Mar. 29	Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Elicio Therapeutics, Inc.(NasdaqGM:ELTX) dropped from Russell Microcap Index

June 23, 2023 at 12:00 am EDT

Latest news about Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	Apr. 05	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC	Mar. 18	CI
Elicio Therapeutics, Inc. announced that it expects to receive $5.999999 million in funding from Gkcc, LLC	Mar. 17	CI
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	Jan. 25	CI
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial	Jan. 11	MT
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	Jan. 11	CI
Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	Jan. 09	CI
Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding	Dec. 21	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer	23-10-12	CI
Elicio Therapeutics Says Solid Tumor Phase 1 Study of ELI-002 Showed 'Promising' Preliminary Relapse-Free Survival Data	23-09-28	MT
Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of Eli-002 At AACR Special Conference: Pancreatic Cancer	23-09-27	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) dropped from Russell 3000E Index	23-06-23	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) dropped from Russell Microcap Index	23-06-23	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) dropped from Russell Microcap Value Index	23-06-23	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) dropped from Russell 3000E Value Index	23-06-23	CI
Elicio Therapeutics Reports 'Positive' Results From Phase 1 Cancer Immunotherapy Trial; Shares Jump Premarket	23-06-05	MT
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to NASDAQ Composite Index	23-06-05	CI
Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer	23-06-03	CI
Angion Biomedica Corp. has Changed its Name to Elicio Therapeutics, Inc	23-06-01	CI
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	23-05-31	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others for $49 million in a reverse merger transaction.	23-01-16	CI

Chart Elicio Therapeutics, Inc.

Duration

Period

More charts

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract No: 2636

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.38 USD

Average target price

10 USD

Spread / Average Target

+6.61%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ELICIO THERAPEUTICS, INC.	+24.70%	95.87M
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.17%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research